Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Omeros Co. (NASDAQ:OMER) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $22.50.

OMER has been the topic of a number of research reports. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Thursday, December 19th. Rodman & Renshaw initiated coverage on shares of Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective for the company. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Finally, D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a report on Thursday.

Omeros Stock Up 3.1 %

Shares of NASDAQ:OMER opened at $9.18 on Friday. The company’s fifty day moving average is $9.25 and its two-hundred day moving average is $5.96. The company has a market cap of $531.98 million, a P/E ratio of -3.97 and a beta of 2.01. Omeros has a 12-month low of $2.61 and a 12-month high of $13.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets boosted its stake in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 7,016 shares in the last quarter. MML Investors Services LLC boosted its stake in shares of Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares during the last quarter. SPC Financial Inc. bought a new position in Omeros in the third quarter valued at approximately $77,000. SG Americas Securities LLC bought a new position in shares of Omeros in the 3rd quarter worth $80,000. Finally, AQR Capital Management LLC acquired a new position in shares of Omeros during the 2nd quarter worth about $105,000. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.